Journal
BIOTECHNOLOGY LETTERS
Volume 32, Issue 5, Pages 609-622Publisher
SPRINGER
DOI: 10.1007/s10529-010-0214-z
Keywords
Conjugate; Fab; Fusion protein; Immunoglobulin; PEGylation; Pharmacokinetics; Polysialylation; scFv
Categories
Funding
- Imperial College, Cancer Research UK [C18960]
- European Union [LSHC-CT-2006-037489]
Ask authors/readers for more resources
With the advent of antibody fragments and alternative binding scaffolds, that are devoid of Fc-regions, strategies to increase the half-life of small proteins are becoming increasingly important. Currently, the established method is chemical PEGylation, but more elaborate approaches are being described such as polysialylation, amino acid polymers and albumin-binding derivatives. This article reviews the main strategies for pharmacokinetic enhancement, primarily chemical conjugates and recombinant fusions that increase apparent molecular weight or hydrodynamic radius or interact with serum albumin which itself has a long plasma half-life. We highlight the key chemical linkage methods that preserve antibody function and retain stability and look forward to the next generation of technologies which promise to make better quality pharmaceuticals with lower side effects. Although restricted to antibodies, all of the approaches covered can be applied to other biotherapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available